EUVIMEDEUVIMED entdecken
Multizentrische Studie

Long‐term safety and durability of multiple anti‐TNFα switches in pediatric inflammatory bowel disease: A Italian society of pediatric gastroenterology, hepatology and nutrition multicenter study

Valeria Dipasquale, Saverio Pochesci, Rossella Morello, Luca Scarallo, Lorenzo Fioretti, Francesco Graziano, Michele Citrano, Chiara Longo, Serena Arrigo, Annalisa Carciofi, Simona Gatti, Flavio Labriola und 3 weitere

Journal of Pediatric Gastroenterology and Nutrition · 2026

DOI: 10.1002/jpn3.70443 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2026. Verfasst von Valeria Dipasquale und 14 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Gastroenterology and Cystic Fibrosis Unit, University Hospital "G. Martino", Messina, Italy. Hauptthemen laut MEDLINE: Infliximab, Adalimumab, Inflammatory Bowel Diseases, Drug Substitution. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: None.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the long‐term safety, immunogenicity, and treatment durability of multiple sequential intramolecular switches of anti–tumor necrosis factor (TNF)‐α agents (infliximab and adalimumab) in pediatric inflammatory bowel disease (IBD).

Methods

A multicenter, retrospective cohort study was conducted across seven Italian pediatric IBD centers (2011–2024) under the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition IBD Working Group. Patients diagnosed with IBD before 18 years and undergoing ≥1 anti–TNF‐α switch with ≥18 months follow‐up were included. Switches were classified as originator‐to‐biosimilar, biosimilar‐to‐originator, or biosimilar‐to‐biosimilar, and as medically or nonmedical (supply‐driven). Therapeutic switches between different anti–TNF‐α molecules (e.g., infliximab to adalimumab or vice versa) were not included. The primary outcome was treatment persistence; secondary outcomes included relapse, adverse events (AEs), and anti‐drug antibody detection.

Results

A total of 185 patients (57% male; median age 11.9 years) were included; 73.5% had Crohn's disease. Over a median 5.5‐year follow‐up, 28% underwent a second and 9% a third switch, predominantly nonmedical and biosimilar‐to‐biosimilar. After the first switch, relapse occurred in 8.1%, infusion reactions in 4.3%, and other AEs in 3.8%, with no differences across switch types. Treatment discontinuation occurred in 21.1%, mainly due to loss of response (48.7%) or AEs (28.2%). Medically driven switching independently predicted discontinuation (hazard ratio; 3.1, 95% confidence interval [CI] 1.5–6.4, p = 0.002). Treatment durability did not differ by number of switches (log‐rank p = 0.635). At final follow‐up, 92.5% were in remission.

Conclusions

Multiple, predominantly nonmedical anti–TNF‐α switches were not associated with increased relapse, AEs, or reduced durability in pediatric IBD. These findings support the safety of sequential switching under physician supervision, though prospective pediatric data remain warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InfliximabAdalimumabInflammatory Bowel DiseasesDrug SubstitutionTumor Necrosis Factor-alphaBiosimilar PharmaceuticalsGastrointestinal AgentsHumansChildMaleFemaleRetrospective StudiesItalyAdolescentTreatment OutcomeCrohn Disease

Stichwörter der Autor:innen

adverse eventsbiosimilarschildrenmultiple switchingtreatment durability

Substanzen

InfliximabAdalimumabTumor Necrosis Factor-alphaBiosimilar PharmaceuticalsGastrointestinal Agents

Autor:innen und Institutionen

  • Pediatric Gastroenterology and Cystic Fibrosis Unit, University Hospital "G. Martino", Messina, Italy.
  • Gastroenterology and Nutrition Unit, Meyer Children's Hospital, Florence, Italy.
  • Pediatric Unit, Villa Sofia Cervello Hospital, Palermo, Italy.
  • Pediatric Gastroenterology and Endoscopy, IRCCS Istituto "Giannina Gaslini", Genoa, Italy.
  • Department of Pediatrics, Polytechnic University of Marche, Ancona, Italy.
  • Pediatric Gastroenterology Unit, Maggiore "CA Pizzardi" Hospital Bologna, Bologna, Italy.

ORCID-Profile: Claudio Romano

Förderung

  • None

Zitieren

APA

Dipasquale, V., Pochesci, S., Morello, R., Scarallo, L., Fioretti, L., Graziano, F., Citrano, M., Longo, C., Arrigo, S., Carciofi, A., Gatti, S., Labriola, F., Bramuzzo, M., Lionetti, P., & Romano, C. (2026). Long‐term safety and durability of multiple anti‐TNFα switches in pediatric inflammatory bowel disease: A Italian society of pediatric gastroenterology, hepatology and nutrition multicenter study. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70443

Vancouver

Dipasquale V, Pochesci S, Morello R, Scarallo L, Fioretti L, Graziano F, et al. Long‐term safety and durability of multiple anti‐TNFα switches in pediatric inflammatory bowel disease: A Italian society of pediatric gastroenterology, hepatology and nutrition multicenter study. Journal of Pediatric Gastroenterology and Nutrition. 2026. doi:10.1002/jpn3.70443

BibTeX
@article{Dipasquale2026,
  author = {Dipasquale, Valeria and Pochesci, Saverio and Morello, Rossella and Scarallo, Luca and Fioretti, Lorenzo and Graziano, Francesco and Citrano, Michele and Longo, Chiara and Arrigo, Serena and Carciofi, Annalisa and Gatti, Simona and Labriola, Flavio and Bramuzzo, Matteo and Lionetti, Paolo and Romano, Claudio},
  title = {Long‐term safety and durability of multiple anti‐TNFα switches in pediatric inflammatory bowel disease: A Italian society of pediatric gastroenterology, hepatology and nutrition multicenter study},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2026},
  doi = {10.1002/jpn3.70443}
}
Kostenlos starten →